Format
Items per page
Sort by

Send to:

Choose Destination

Results: 15

Related Articles by Review for PubMed (Select 21992533)

1.

Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients.

Vincenti F, Larsen CP, Alberu J, Bresnahan B, Garcia VD, Kothari J, Lang P, Urrea EM, Massari P, Mondragon-Ramirez G, Reyes-Acevedo R, Rice K, Rostaing L, Steinberg S, Xing J, Agarwal M, Harler MB, Charpentier B.

Am J Transplant. 2012 Jan;12(1):210-7. doi: 10.1111/j.1600-6143.2011.03785.x. Epub 2011 Oct 12.

2.

A network meta-analysis of the efficacy of belatacept, cyclosporine and tacrolimus for immunosuppression therapy in adult renal transplant recipients.

Goring SM, Levy AR, Ghement I, Kalsekar A, Eyawo O, L'Italien GJ, Kasiske B.

Curr Med Res Opin. 2014 Aug;30(8):1473-87. doi: 10.1185/03007995.2014.898140. Epub 2014 Apr 3. Review.

PMID:
24628478
3.

Belatacept: in adult kidney transplant recipients.

Garnock-Jones KP.

BioDrugs. 2012 Dec 1;26(6):413-24. doi: 10.2165/11208900-000000000-00000. Review.

PMID:
22928660
4.

Belatacept in kidney transplantation.

Wojciechowski D, Vincenti F.

Curr Opin Organ Transplant. 2012 Dec;17(6):640-7. doi: 10.1097/MOT.0b013e32835a4c0d. Review.

PMID:
23044530
5.

Risk of posttransplant lymphoproliferative disorder associated with use of belatacept.

Martin ST, Powell JT, Patel M, Tsapepas D.

Am J Health Syst Pharm. 2013 Nov 15;70(22):1977-83. doi: 10.2146/ajhp120770. Review.

PMID:
24173007
6.

Belatacept: a novel biologic for maintenance immunosuppression after renal transplantation.

Martin ST, Tichy EM, Gabardi S.

Pharmacotherapy. 2011 Apr;31(4):394-407. doi: 10.1592/phco.31.4.394. Review.

PMID:
21449628
7.

Belatacept: a new biologic and its role in kidney transplantation.

Su VC, Harrison J, Rogers C, Ensom MH.

Ann Pharmacother. 2012 Jan;46(1):57-67. doi: 10.1345/aph.1Q537. Epub 2012 Jan 3. Review.

PMID:
22215686
8.

Biological agents in kidney transplantation: belatacept is entering the field.

Wéclawiak H, Kamar N, Ould-Mohamed A, Cardeau-Desangles I, Rostaing L.

Expert Opin Biol Ther. 2010 Oct;10(10):1501-8. doi: 10.1517/14712598.2010.514901. Review.

PMID:
20726688
9.

How the development of new biological agents may help minimize immunosuppression in kidney transplantation: the impact of belatacept.

Wojciechowski D, Vincenti F.

Curr Opin Organ Transplant. 2010 Dec;15(6):697-702. doi: 10.1097/MOT.0b013e3283402b5c. Review.

PMID:
20930638
10.

Belatacept utilization recommendations: an expert position.

Grinyó JM, Budde K, Citterio F, Charpentier B.

Expert Opin Drug Saf. 2013 Jan;12(1):111-22. doi: 10.1517/14740338.2013.748747. Epub 2012 Dec 4. Review.

PMID:
23206310
11.

Belatacept: a new era of immunosuppression?

El-Charabaty E, Geara AS, Ting C, El-Sayegh S, Azzi J.

Expert Rev Clin Immunol. 2012 Aug;8(6):527-36. Review.

PMID:
22992146
12.

Belatacept : a new biological agent for maintenance immunosuppression in kidney transplantation.

Arora S, Tangirala B, Osadchuk L, Sureshkumar KK.

Expert Opin Biol Ther. 2012 Jul;12(7):965-79. doi: 10.1517/14712598.2012.683522. Epub 2012 May 8. Review.

PMID:
22564126
13.

Potential of emerging immunosuppressive strategies to improve the posttransplant cardiovascular risk profile.

Djamali A, Pietrangeli CE, Gordon RD, Legendre C.

Kidney Int Suppl. 2010 Sep;(118):S15-21. doi: 10.1038/ki.2010.211. Review. Erratum in: Kidney Int. 2010 Dec;78(11):1192.

14.

Co-stimulatory blockade with belatacept in kidney transplantation.

Chopra B, Sureshkumar KK.

Expert Opin Biol Ther. 2014 May;14(5):563-7. doi: 10.1517/14712598.2014.896332. Epub 2014 Mar 12. Review.

PMID:
24620724
15.

Belatacept: from rational design to clinical application.

Wekerle T, Grinyó JM.

Transpl Int. 2012 Feb;25(2):139-50. doi: 10.1111/j.1432-2277.2011.01386.x. Epub 2011 Dec 7. Review.

PMID:
22151353
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk